OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: the PREDICT Study

ObjectiveTo evaluate fremanezumab quarterly or monthly vs placebo on health-related quality of life, health status, patients' global impression of change, and productivity in patients with chronic migraine (CM).MethodsHALO CM was a double-blind, placebo-controlled trial in patients with CM. Patients were randomized 1:1:1 to treatment with fremanezumab quarterly (675 mg at baseline, placebo at weeks 4 and 8), fremanezumab monthly (225 mg at baseline, weeks 4 and 8), or placebo. This article assessed the effect of treatment with fremanezumab on health-related quality of life and productivity using the following prespecified assessments: the Migraine-Specific Quality of Life (MSQoL) questionnaire at baseline and weeks 4, 8, and 12; Patient Global Impression of Change (PGIC) questionnaire at weeks 4, 8, and 12; and EuroQoL 5-dimension, 5-response level (EQ-5D-5L) questionnaire and Work Productivity and Activity Impairment: General Health (WPAI:GH) questionnaire at baseline and week 12.ResultsThe full analysis set included 1,121 patients: 375 patients with quarterly dosing, 375 with monthly dosing, and 371 with placebo. Fremanezumab quarterly and monthly was associated with significant improvements over placebo in change from baseline mean scores in MSQoL domains (all, p < 0.05) to week 12. At week 12, fremanezumab also showed significant improvements in EQ-5D-5L visual analog scale (p < 0.05) and PGIC scores (p < 0.0001) as well as significant reductions from baseline in WPAI:GH scores (p < 0.01) and presenteeism (impairment while working; p < 0.05) vs placebo.ConclusionsFremanezumab quarterly or monthly was associated with improvement over placebo in migraine-specific quality of life, overall health status, patients' global impression of change with treatment, and productivity in patients with CM.ClinicalTrials.gov identifierNCT02621931.Classification of evidenceThis study provides Class II evidence that in patients with CM, treatment with fremanezumab quarterly or monthly is associated with improvements in health-related quality of life and productivity.

Download Full-text

A Prospective Observational Cohort Study on Pharmacological Habitus, Headache-Related Disability and Psychological Profile in Patients with Chronic Migraine Undergoing OnabotulinumtoxinA Prophylactic Treatment

Toxins ◽

10.3390/toxins11090504 ◽

2019 ◽

Vol 11 (9) ◽

pp. 504 ◽

Cited By ~ 4

Author(s):

Gandolfi ◽

Donisi ◽

Marchioretto ◽

Battista ◽

Smania ◽

...

Keyword(s):

Quality Of Life ◽

Psychological Distress ◽

Coping Strategies ◽

Chronic Migraine ◽

Prophylactic Treatment ◽

Moderate Intensity ◽

Psychological Profile ◽

Factors Affecting ◽

Acute Medication

Chronic Migraine (CM) is a disabling neurologic condition with a severe impact on functioning and quality of life. Successful therapeutic management of patients with CM is complex, and differences in therapeutic response could be attributable to genetically determined factors, sensitivity to pharmacological treatment, psychosocial and relational factors affecting the patient’s compliance and approach on the therapeutic treatment. The aim of this prospective observational study was to explore self-efficacy, coping strategies, psychological distress and headache-related disability in a cohort of 40 patients with CM (mean age: 46.73; standard deviation 13.75) treated with OnabotulinumtoxinA and the relationship between these clinical and psychological aspects and acute medication consumption during OnabotulinumtoxinA prophylactic treatment. Patients presented an overall significant reduction in the Headache Index (HI) (p < 0.001), HI with severe intensity (p = 0.009), and total analgesic consumption (p = 0.003) after the prophylactic treatment. These results are in line with the literature. Despite this, higher nonsteroidal anti-inflammatory drugs consumption was associated with higher psychological distress, higher HI with severe and moderate intensity, and worse quality of life. Conversely, triptans consumption was correlated with HI of mild intensity, and problem-focused coping strategies. To conclude, the psychological profile, and in particular, the psychological distress and specific coping strategies might influence the self-management of acute medication.

Download Full-text

PND82 IMPACT OF EPTINEZUMAB ON THE HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF PATIENTS WITH EPISODIC OR CHRONIC MIGRAINE: SF-36 ANALYSIS BY MONTHS 1 AND 3 ACROSS THE SPECTRUM OF MIGRAINE

Value in Health ◽

10.1016/j.jval.2019.04.1355 ◽

2019 ◽

Vol 22 ◽

pp. S285 ◽

Cited By ~ 1

Author(s):

M. Diamond ◽

R.B. Lipton ◽

R. Horblyuk ◽

J. Hirman ◽

R. Cady ◽

...

Keyword(s):

Quality Of Life ◽

Chronic Migraine ◽

Health Related Quality ◽

Sf 36 ◽

Related Quality ◽

Health Related

Download Full-text

Low cognitive reserve is associated with chronic migraine with medication overuse and poor quality of life

Cephalalgia ◽

10.1177/0333102414553822 ◽

2014 ◽

Vol 35 (8) ◽

pp. 683-691 ◽

Cited By ~ 9

Author(s):

Marian Gómez-Beldarrain ◽

Ane Anton-Ladislao ◽

Urko Aguirre-Larracoechea ◽

Isabel Oroz ◽

Juan Carlos García-Moncó

Keyword(s):

Quality Of Life ◽

Chronic Migraine ◽

Cognitive Reserve ◽

Medication Overuse ◽

Univariate Analysis ◽

Poor Quality ◽

Anxiety And Depression ◽

Cross Sectional ◽

Sf 36

Objective The objective of this article is to test the hypothesis that cognitive reserve (CR) is related to migraine chronification, medication overuse and poor quality of life in migraineurs. Design/methods A cross-sectional study on patients with chronic migraine with medication overuse (CM-MOH), episodic migraine (EM), and controls, matched by sex, age and education, was carried out. CR was assessed by a specific questionnaire, and quality of life was measured by general and specific questionnaires (SF-36 and MSQoL). Migraine Disability Assessment Scale and Beck questionnaires for depression and anxiety were used. Medication dependence was evaluated by the medication-dependence questionnaire in headache (MDQ-H). Results Fifty-five individuals were enrolled: 18 CM-MOH patients (32.73%), 22 EM patients (40%) and 15 controls (27.27%). Fifty (90.91%) of them were females and aged 43.53 (7.54) years. Univariate analysis showed a significant association between the study group and CR, and all items of the SF-36, anxiety and depression questionnaires, MSQoL and MDQ-H. The lower CR and CM-MOH group were related to a worse quality of life, more anxiety and depression and the highest medication dependence scores. Multivariate analysis showed that higher CR scores were related to higher quality of life as measured by the physical and mental composite scores of the SF-36, and to lower anxiety (beta = −1.08, p = 0.001) and depression (beta = −0.56, p = 0.03) levels. Focusing on MSQoL, the increase in CR was predictive of a better quality of life (beta = 1.88, p < 0.0001). By all the models, the explained variance of the sample ranged from 39% (mental composite score) to 58% (MSQoL). Conclusions Low CR appears to be an independent factor associated with the deterioration of quality of life, the presence of anxiety and depression, and drug dependence and medication overuse in CM-MOH.

Download Full-text

Validation of the Korean Migraine-Specific Quality of Life Questionnaire Version 2.1 in Episodic and Chronic Migraine

Journal of Oral & Facial Pain and Headache ◽

10.11607/ofph.1769 ◽

2017 ◽

Vol 31 (3) ◽

pp. 251-256 ◽

Cited By ~ 2

Author(s):

Jong-Geun Seo ◽

Sung-Pa Park

Keyword(s):

Quality Of Life ◽

Chronic Migraine ◽

Life Questionnaire ◽

Quality Of Life Questionnaire ◽

Questionnaire Version

Download Full-text